Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 13, 2020

View Archived Issues

Enrollment ongoing in phase I/II ASPEN-02 study of ALX-148 plus azacytidine in MDS

Oncostellae initiates phase Ib/IIa study of OST-122 in ulcerative colitis

Venthera begins first-in-human trial of VT-30

Drug repurposing study suggests paromomycin as a dual targeting drug against SARS-CoV-2

FKBP9P1 lncRNA is upregulated in HNSCC and its knockdown inhibits malignant progression

Microbiome metabolite affects neuropathic pain

Prying the BBB back open for improved LSD treatment

Dosing starts in phase I study of AMP-945

PENELOPE-B study of palbociclib does not meet primary endpoint

Potential MND treatments move a step forward

Galectin-7, a new biomarker for pre-eclampsia

UBAP2 as potential therapeutic target in pancreatic cancer

FDA clears IND for trials of ASC-42 for NASH

FDA issues complete response letter for Avenue's intravenous tramadol

Sorrento licenses PSC's mesenchymal stem cells for COVID-19-associated ARDS

Pivotal trial of Dupixent in children with moderate to severe asthma meets primary endpoint

SynAct advances phase IIa study of AP-1189 in rheumatoid arthritis

AstraZeneca advances AZD-7442 into phase III for COVID-19

Memorial Sloan Kettering, HHS patent ADAM 17-binding molecules

Celltrion begins phase III postexposure prophylaxis trial of CT-P59 for COVID-19

Janssen Pharmaceutica discloses new MAP4K1 inhibitors

New HDAC6 inhibitors discovered at 2681603 Ontario

Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical present new ERK inhibitors

Axis Therapeutics collaborates with PharmaEssentia on TCR-T cell therapy in Taiwan

Registrational trial of penpulimab for nasopharyngeal cancer meets key endpoints

Promising cohort 2 data reported from pivotal study of Padcev in urothelial cancer

Topline data reported from EAP study with aviptadil for critical COVID-19

Phase I/II study of PLX-PAD for GvHD cleared to advance to cohort 2

New phase III trial evaluates hIVIG to treat COVID-19

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...